Indian drug giant Sun Pharma has entered into an agreement to test a novel botanical dengue drug recently developed by an international non-profit research organisation, hoping to bring it to the market in the next four years.
The drug, Cipa, was developed through a joint project started in 2007 by the Delhi arm of International Centre for Genetic Engineering and Biotechnology (ICGEB) along with Department of Biotechnology (DBT) and Ranbaxy Research Laboratory. Ranbaxy Research Laboratory is now a part of Sun Pharma. As part of the May 4 agreement between Sun Pharma and ICGEB, the pharma company will now see the drug, which has completed pre-clinical work, through all phases of clinical studies. ICGEB will provide its technical and pre-clinical expertise and work exclusively with the drug maker for the development of the drug and clinical treatment strategies based on botanical and phyto-pharmaceuticals, according to a joint statement.